Eikon Therapeutics, Inc. (EIKN)

Eikon Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2024	Dec 31, 2023
Net Income	-309.52	-243.81	-242
Depreciation & Amortization	19.18	15.94	-3.37
Share-Based Compensation	-	12.43	9.54
Other Operating Activities	70.17	80.65	44.98
Operating Cash Flow	-220.18	-134.8	-190.85
Capital Expenditures	-36.55	-84.8	-28.51
Change in Investments	-	236.15	165.46
Investing Cash Flow	-164.26	151.35	136.95
Share Issuance / Repurchase	-	0.24	105.81
Financing Cash Flow	351.06	0.24	105.81
Net Cash Flow	-33.37	16.8	51.91
Free Cash Flow	-256.73	-219.6	-219.36

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).